Page last updated: 2024-08-22

pn 401 and Dihydropyrimidine Dehydrogenase Deficiency

pn 401 has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Hu, EH; Keung, YK; Yu, D; Zurayk, M1
Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW1
Robert, J1
Amylidi, AL; Angelaki, A; Aravantinos, G; Boumpoucheropoulos, S; Fildissis, G; Lampropoulou, DI; Laschos, K; Nanou, E; Nasioulas, G; Papadopoulou, E; Soupos, N; Zidianakis, V1
Diasio, RB; Saif, MW1

Reviews

2 review(s) available for pn 401 and Dihydropyrimidine Dehydrogenase Deficiency

ArticleYear
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:1

    Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Middle Aged; Mutation; Uridine

2019
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:3

    Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Neoplasms; Uridine

2020

Other Studies

3 other study(ies) available for pn 401 and Dihydropyrimidine Dehydrogenase Deficiency

ArticleYear
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
    Toxicology and applied pharmacology, 2018, 08-15, Volume: 353

    Topics: Acetates; Animals; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Drug Overdose; Female; Fluorouracil; Mice; Survival Analysis; Uridine

2018
[5-FU: At last!]
    Bulletin du cancer, 2019, Volume: 106, Issue:3

    Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Neoplasms; Practice Guidelines as Topic; Pyrimidines; Uracil; Uridine

2019
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1

    Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Male; Pancreatic Neoplasms; Severity of Illness Index; Time Factors; Uridine

2016